SUCCESS AND FAILURE OF INITIAL ANTIRETROVIRAL THERAPY (ART) IN ADULTS: AN UPDATED SYSTEMATIC REVIEW INCLUDING 77,999 SUBJECTS FROM 1994 TO 2017

Carr A1, Richardson R1, Riches S1, Liu Z2

Centre for Applied Medical Research, St Vincent’s Hospital1, and University of New South Wales2, Sydney, Australia

Background:
We updated a prior (1994 to 2012) systematic review of adult initial ART efficacy through Week 144.

Methods:
Studies (1/2013-7/2017) were drawn from PubMed, ClinicalTrials.gov, Cochrane Library, and HIV conferences; study design, eligibility, subject and ART data were abstracted. Summary measures are expressed as group size-weighted means. Mixed-effect, meta-regression was used to identify sources of efficacy heterogeneity.

Results:
We analysed 354 groups (181 studies, 77,999 subjects [37,875 new]): baseline age 36.9 years, 74.7% men, 61.0% white, CD4 262 cells/mm³, HIV viral load 4.8 logs. Subjects took 4.8 pills (including placebo) in 1.6 doses/day. Principal backbones were tenofovir (TDF/TAF)/emtricitabine (44.2%), thymidine-based (27.7%), and abacavir-lamivudine (9.7%). Principal anchors were non-nucleoside analogue (49.7%), boosted protease inhibitor (28.1%) and integrase inhibitor (INSTI; 11.5%). Data were highly heterogeneous ($I^2$=96.1%). Mean ITT efficacy (RNA<50 cp/mL) was 71.3%, 63.5% (145 groups) and 61.8% (48 groups) at Weeks 48, 96, and 144, respectively. Week-48 efficacy increased substantially over time (p-trend<0.0001; Figure 1). For post-2010 studies, Week 48, 96 and 144 efficacy was 83.8%, 79.9% and 77.1%, respectively. Independent predictors of greater efficacy at Week 48 were pre-ART genotyping (vs. none: adjusted difference 4.3% [1.4,7.2], p=0.0003); higher baseline CD4 counts (per 100 CD4-cell increment: 2.2% [1.0,3.4], p=0.0003); once-daily ART (vs. 2 doses/day: 3.4% [0.9,5.9]; p=0.008); INSTI-based ART (vs. other anchors: p<0.001); and ART including TDF/TAF-FTC (vs. other nucleosides, p=0.02). Cessation at Weeks 48, 96 and 144 was 20.5%, 26.9% and 29.4%, respectively. Cessation by Week 144 overall and for adverse events (8.9%) declined substantially over time, but cessation for virological failure (5.2%) did not.

Conclusions:
Initial ART continues to improve, but >20% of post-2010 subjects failed over 3 years. All guidelines should list INSTI-based initial ART as preferred. Strategies are needed to improve access to pre-ART genotyping and to increase early initiation of once-daily ART.
Figure 1  Efficacy at Week 48 by year of study commencement